For glioma patients, presence of IDH mutations is of clinical relevance as patients harboring IDH mutated gliomas have a better survival compared to those with wildtype IDH. The prognostic significance of IDH mutations has led to its incorporation in the WHO 2016 update to classify gliomas [12]. This evidence concerns the gene IDH1 and central nervous system cancer.